<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592653</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 4230-003</org_study_id>
    <nct_id>NCT04592653</nct_id>
  </id_info>
  <brief_title>A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment</brief_title>
  <acronym>ARTISTRY-3</acronym>
  <official_title>Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effects of ALKS 4230 monotherapy on&#xD;
      the tumor microenvironment of a variety of advanced, malignant solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in density (cell counts per mm2) of immune cell (including total T cells, CD8+ T cells, CD56+ cells and Treg cells)</measure>
    <time_frame>From the time of the Patient's pre-treatment biopsy to the time of the Patient's on-treatment biopsy</time_frame>
    <description>Changes in density (cell counts per mm2) of immune cell (including total T cells, CD8+ T cells, CD56+ cells and Treg cells) based on immunohistochemistry (IHC) and/or immunofluorescence (IF) in the TME between pretreatment and on-treatment (Cycle 2 Day 8) paired tumor biopsies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ratios (including T/Treg, CD8+/Treg, CD56+/Treg) based on immunohistochemistry (IHC) and/or immunofluorescence (IF) in the TME between pretreatment and on-treatment (Cycle 2 Day 8) paired tumor biopsies</measure>
    <time_frame>From the time of the Patient's pre-treatment biopsy to the time of the Patient's on-treatment biopsy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with objective evidence of Complete Response (CR)/immune CR (iCR)</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with Complete Response (CR)/immune CR (iCR)</measure>
    <time_frame>Time from the first documentation of complete response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with objective evidence of Partial Response (PR)/immune PR (iPR)</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with Partial Response (PR)/immune PR (iPR)</measure>
    <time_frame>Time from the first documentation of partial response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related Adverse Events</measure>
    <time_frame>Time from first dose of study drug to the end of study (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related Serious Adverse Events</measure>
    <time_frame>Time from first dose of study drug to the end of study (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug-related Adverse Events leading to discontinuation</measure>
    <time_frame>Time from first dose of study drug to the end of study (estimated up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ALKS 4230</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 14 or 21 days), assessed up to 24 months</time_frame>
    <description>Concentration data will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum will be assayed for the presence of anti-ALKS 4230 antibodies</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 14 or 21 days), assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in absolute cell numbers (including total T cells, CD8+ T cells, NK cells and Treg cells)</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 14 or 21 days), assessed up to 24 months</time_frame>
    <description>Changes in absolute cell numbers (including total T cells, CD8+ T cells, NK cells and Treg cells) between pretreatment and on-treatment serial peripheral blood samples obtained from patients being treated with ALKS 4230 monotherapy and with the combination of ALKS 4230 plus pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ratios (including T/Treg, CD8+/Treg, NK/Treg) between pretreatment and on treatment</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 14 or 21 days), assessed up to 24 months</time_frame>
    <description>Changes in ratios (including T/Treg, CD8+/Treg, NK/Treg) between pretreatment and on-treatment serial peripheral blood samples obtained from patients being treated with ALKS 4230 monotherapy and with the combination of ALKS 4230 plus pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of proinflammatory cytokines, including IFNγ, TNF-α, IL-1B, IL-6, IL-10, will be assessed using a multiplex method from initiation of therapy</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 14 or 21 days), assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in absolute numbers of circulating leukocytes</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 14 or 21 days), assessed up to 24 months</time_frame>
    <description>Changes in absolute numbers of circulating leukocytes between pretreatment and on-treatment serial peripheral blood samples obtained from patients being treated with ALKS 4230 monotherapy and with the combination of ALKS 4230 plus pembrolizumab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALKS 4230 will be administered via Intravenous (IV) infusion given daily for 5 consecutive days followed by an off-treatment period. Starting on Cycle 3, Day 1 of each cycle, Pembrolizumab will be administered via IV infusion followed by IV infusion of ALKS 4230.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 4230</intervention_name>
    <description>IV infusion over 30 minutes</description>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion over 30 minutes</description>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed diagnosis of an advanced&#xD;
             solid malignancy (cutaneous melanoma, RCC, TNBC, Microsatellite-stable (MSS)&#xD;
             colorectal cancer, Microsatellite-high (MSI-H) solid tumors [not otherwise specified],&#xD;
             or ovarian cancer) after treatment failure or intolerance to at least one established,&#xD;
             indication-specific therapy.&#xD;
&#xD;
          -  Patients must be willing to provide tumor tissue biopsy and have accessible lesions&#xD;
             for biopsy.&#xD;
&#xD;
          -  All patients must provide a baseline biopsy from no more than 3 months prior to&#xD;
             screening, and at least 4 weeks after completion of last anti-cancer therapy.&#xD;
&#xD;
          -  Patients must have disease that is measurable by RECIST 1.1.&#xD;
&#xD;
          -  Patients must demonstrate adequate organ function&#xD;
&#xD;
          -  Female patients of childbearing potential should have a negative pregnancy test within&#xD;
             72 hours prior to receiving the first dose of study medication&#xD;
&#xD;
          -  Patients must agree to follow contraceptive requirements defined in the protocol&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding or is planning to become pregnant during the&#xD;
             study period.&#xD;
&#xD;
          -  Patients with an active infection or with a fever ≥38.5°C within 3 days of the first&#xD;
             scheduled day of dosing&#xD;
&#xD;
          -  Patients with primary CNS malignancy&#xD;
&#xD;
          -  Patients with active or symptomatic central nervous system metastases unless the&#xD;
             metastases have been treated by surgery and/or radiation therapy and/or gamma knife,&#xD;
             the subject has been tapered to a dose of 10 mg of prednisone (or equivalent) or less&#xD;
             of corticosteroids for at least 2 weeks before the first dose, and the subject is&#xD;
             neurologically stable. Patients with leptomeningeal disease are excluded.&#xD;
&#xD;
          -  Patients with hypersensitivity to pembrolizumab, ALKS 4230, or any of their excipients&#xD;
&#xD;
          -  Patients who have received systemic immunomodulatory agents within 6 weeks prior to&#xD;
             the first scheduled day of dosing&#xD;
&#xD;
          -  Patients who have received prior IL-2-based or IL-15-based cytokine therapy at any&#xD;
             time in the past&#xD;
&#xD;
          -  Patients who require pharmacologic doses of systemic corticosteroids (greater than 10&#xD;
             mg of prednisone daily or equivalent); however, topical, ophthalmologic, and&#xD;
             inhalational steroids are permitted&#xD;
&#xD;
          -  Patients with an uncontrollable bleeding disorder&#xD;
&#xD;
          -  Patients known to be positive for human immunodeficiency virus and/or history of&#xD;
             hepatitis B, or C infections or is known to be positive for hepatitis B antigen&#xD;
             (HBsAg)/hepatitis B virus (HBV) DNA or hepatitis C antibody (Hep C Ab) or RNA.&#xD;
&#xD;
          -  Patients with any other concurrent uncontrolled illness, including mental illness or&#xD;
             substance abuse, which may interfere with the ability of the subject to cooperate and&#xD;
             participate in the study.&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>888-235-8008 (US Only)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>1-571-599-2702 (Global)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkermes</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Oncology</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

